ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer

Min Kyoung Kim, Kyung Ja Cho, Gui Young Kwon, Seung Il Park, Yong Hee Kim, Jong Hoon Kim, Ho Young Song, Ji Hoon Shin, Hwoon Yong Jung, Gin Hyug Lee, Kee Don Choi, Sung Bae Kim

Research output: Contribution to journalArticlepeer-review

70 Scopus citations


We assessed whether expression of excision repair cross-complementation group 1 (ERCC1) and/or thymidylate synthase (TS) can predict clinical outcome after preoperative chemoradiotherapy (CRT) in patients with localised oesophageal cancer. Paraffin-embedded pretreatment tumour specimens collected by endoscopic biopsy from patients treated with preoperative CRT (5-fluorouracil/cisplatin or capecitabine/cisplatin plus radiation) were analysed by immunohistochemical assay. Between March 1993 and June 2005, 129 patients were treated with preoperative CRT followed by surgery; of these, 108 biopsy specimens were available for analysis, and 40% and 35% were positive for ERCC1 and TS, respectively. Patients with ERCC1-negative (p < 0.001) or TS-negative (p = 0.04) tumours were significantly more likely to achieve pathologic major response. In multivariate analysis, ERCC1 was the only independent variable predicting pathologic response (p < 0.001). Patients with ERCC1-negative tumours showed tendencies toward prolonged overall survival (p = 0.10) and event free survival (p = 0.08). Prospective studies are required to determine the benefit of preoperative CRT in ERCC1-negative tumours.

Original languageEnglish (US)
Pages (from-to)54-60
Number of pages7
JournalEuropean Journal of Cancer
Issue number1
StatePublished - Jan 2008
Externally publishedYes


  • Combined modality therapy
  • ERCC1
  • Oesophageal neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer'. Together they form a unique fingerprint.

Cite this